34 results about "Insulin used" patented technology

Method and system for providing basal profile modification in insulin therapy for use with infusion devices includes periodically monitoring the analyte levels of a patient for a predetermined period of time in order to determine, based on the monitored analyte levels, an appropriate modification factor to be incorporated into the underlying basal profile which was running at the time the periodic monitoring of the analyte levels were performed.

Described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed into the controller. The infusion pump is configured to deliver insulin to a subject. The glucose sensor is configured to sense glucose levels in the subject and provide output signals representative of the glucose levels in the subject. The controller is programmed receives signals from at least one of the glucose sensor and the pump and configured to issue signals to the pump to deliver an amount of insulin determined by a feedback controller that utilizes a model predictive control of the subject based on desired glucose levels, insulin amount delivered and measured glucose levels of the subject. The controller is also configured to deliver insulin using a tuning factor based on either one of an omission index module or a calibration index module.

Described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed in the controller. The infusion pump is configured to deliver insulin. The glucose sensor senses glucose levels in the subject and provide output signals representative of the glucose levels in the subject. The controller is programmed receives signals from at least one of the glucose sensor and the pump and configured to issue signals to the pump to deliver an amount of insulin determined by a feedback controller that utilizes a model predictive control based on desired glucose levels, insulin amount delivered and measured glucose levels of the subject. The controller is also configured to deliver insulin using a tuning factor (R) for a model predictive controller in the microcontroller as a conservative setting otherwise the system maintains a current tuning factor (R) for the controller.

An insulin pump for use in conjunction with a mobile communication terminal capable of measuring a blood glucose level, and a network for transmitting control information for the insulin pump are disclosed. The insulin pump includes an external input port, an output port, memory, a key input unit, a control unit, and a motor driver. The external input port receives information on the amounts of insulin to be injected. The output port outputs information on the amounts of insulin injected. The memory stores the information on the amounts of insulin injected. The key input unit inputs the status of a user. The control unit extracts the information on the amounts of insulin to be injected from the memory. The motor drive operates a soft motor to supply insulin.

Described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed into the controller. The infusion pump is configured to deliver insulin to a subject. The glucose sensor is configured to sense glucose levels in the subject and provide output signals representative of the glucose levels in the subject. The controller is programmed receives signals from at least one of the glucose sensor and the pump and configured to issue signals to the pump to deliver an amount of insulin determined by a feedback controller that utilizes a model predictive control of the subject based on desired glucose levels, insulin amount delivered and measured glucose levels of the subject. The controller is also configured to deliver insulin using a tuning factor based on either one of an omission index module or a calibration index module.

The invention relates to an infusion pipeline for an insulin pump, and belongs to products in the medical field. The infusion pipeline is an insulin infusion pipeline which is provided with a universal Luer taper and cooperates with the insulin pump for use. The infusion pipeline serves as a consumable material of the insulin pump and comprises a needle aid, a needle aid protection sleeve, a sticking needle base, a hose needle, a sticking needle base protection cap, a pipe needle base joint and a pipeline body; the needle aid can be accurately and quickly inserted into a human body with littlepain, double spring design is adopted, one spring is responsible for pushing out the needle, and the other spring is responsible for pulling out and retrieving a steel needle; the needle aid is provided with the protection sleeve, and pressing by accident is prevented; the sticking needle base has the effects of assisting pulling and needle tubing fall off detection and is in rapid sealing connection with the pipe needle base joint; the hose needle is fixed to the position of a four-handle grip of the sticking needle base, and sealing is conducted through silica gel; the direction of the pipeneedle base joint can be adjusted freely to avoid pipeline confusion and knotting; the pipeline adopts the universal Luer taper, and the adaptability is high. The sticking needle base, the needle aid, the pipeline needle base joint and the sticking needle base protection cap are all assembled through pressing clamping locks.

The present invention relates to an insulin analog that has reduced insulin receptor binding affinity for the purpose of increasing the blood half-life of insulin, and long-acting insulin, a conjugate, and a method of preparing long-acting insulin using the same.

The present invention provides an insulin-specific assay and an assay reagent capable of sensitively and specifically assaying insulin using an antibody having a property of reacting with insulin bound to an anti-insulin antibody while not reacting with insulin not bound to an anti-insulin antibody, without being affected by proinsulin and insulin analogs.

The present application discloses the preparation of peptides, including insulin and insulin derivatives, using efficient methods for solid-phase and solution phase peptide synthesis.

The invention discloses a preparation method of polypeptide-insulin nanoparticle. In the invention, insulin monomer is dissolved in a solution, and a certain proportion of polypeptide having the function of inhibiting insulin fibrosis is added at the same time; and then the above solution is stirred for a period of time under certain conditions. , so that the polypeptide and insulin are fully reacted to obtain pentapeptide-insulin supramolecular nanoparticles. The operation of the invention is simple, and the obtained supramolecular nanoparticles do not produce burst release, and have good sustained release effect, and the polypeptide can inhibit the fibrosis of insulin. This product has the potential to solve the dangers of hypoglycemia caused by the sudden release of insulin itself during clinical use and the problems of fibrosis during insulin use, and has broad application prospects in the treatment of type I diabetes and type II diabetes.

The invention relates to the field of biotechnology and medicine, and specifically to insulin-containing preparations used, in particular, for treating diabetes mellitus. The present preparation comprises a mixture of insulin and a pharmacologically acceptable polymer having a hydrodynamic diameter of more than 4.5+ / -0.5 nanometers. As said polymer, at least one polymer having a molecular weight of 20-70 kDa may optimally be used, selected from a group including: dextran, polyethylene glycol and albumin. As regards insulin preparations used in the composition of the preparation, it is possible to use human recombinant insulin and genetically engineered analogues thereof used in the form of commercial preparations. Experiments have shown that using the aforementioned polymers provides insulin preparations with a prolonged effect without the use of chemical or genetic engineering methods to modify insulin molecules. The method is not specific and can thus be applied across a wide range of therapeutic proteins.

The invention discloses a method for directly secreting and expressing mature double-chain insulin glargine by using Saccharomyces cerevisiae. In this method, the chassis cells overexpressing Kex2 are first constructed, and then the tandem signal peptide and codon-optimized insulin glargine DNA are transferred into the chassis cells overexpressing Kex2 to form a Saccharomyces cerevisiae co-expression system, and protein expression and purification are performed to obtain Insulin glargine. This method greatly reduces the difficulty of the insulin glargine production process, simplifies the complicated and complicated multi-step processing process in the middle and downstream of the traditional process, and allows the yeast cells to directly complete the modification work in the cell. At the same time, this method reduces the complexity of purification, and the mature insulin protein can be directly extracted from the culture medium by one-step ion exchange purification with relatively low cost. In addition, due to the avoidance of components such as trypsin, nearly 50% of the by-products in the original process are avoided, and the fermentation efficiency of nutrients such as carbon sources in the medium is improved, which has a good prospect for promotion and application.

The invention discloses an insulin pen suitable for visually impaired patients, which comprises a pen cover, an adjustment cylinder arranged inside the pen cover, a piston body arranged inside the adjustment cylinder, a piston rod fixedly connected with the piston body, and a piston rod installed at the bottom of the adjustment cylinder. The push cylinder at the end, the pen cover is composed of a support sleeve and a connecting shell, and the connecting shell is fixedly connected with the supporting sleeve, and the connecting shell is provided with a dosage elastic reminder device for visually impaired patients to use insulin pens in public places, which is suitable for The insulin pen used by visually impaired patients is provided with a pen cover, and the pen cover is composed of a support sleeve for accommodating the adjustment cylinder and the push cylinder, and a connection shell connecting the support sleeve, and the dose elastic reminder device is provided on the connection shell, Therefore, when the visually impaired patients use it in public places, it can play the role of real-time silent reminder of the dose used by the patient, thereby facilitating the use of the patient.

An insulin infusion set (30) for use with an inserter (40) is disclosed. The infusion set (30) includes an extension set (50). The extension set (50) includes a housing (70), a base (90) and a latching device (82). The base (90) houses a base septum (120) and an infusion cannula (42). The latching device (82) releasably attaches the housing (70) to the base. When the housing (70) is attached to the base (90), a part of the housing (70) extends into and opens the base septum (120).

An insulin infusion set (30) for use with an inserter (40) is disclosed. The infusion set (30) includes an extension set (50). The extension set (50) includes a housing (70), a base (90) and a latching device (82). The base (90) houses a base septum (120) and an infusion cannula (42). The latching device (82) releasably attaches the housing (70) to the base. When the housing (70) is attached to the base (90), a part of the housing (70) extends into and opens the base septum (120).